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Research in context 
Evidence before this study 
Radiotherapy (radiation therapy) after primary surgery for early breast cancer has historically 
been delivered in 5 daily doses (fractions) of 1.8-2Gy per week over at least 5 weeks, but 
randomised phase III clinical trials conducted in Canada, UK and subsequently China and 
Denmark have confirmed the safety and efficacy of 15- or 16-fraction schedules using daily 
fractions of 2.7Gy. Four of these trials published 10-year follow-up data on a total of 7,000 
patients, and 3-week schedules have replaced traditional regimens in many countries over 
the last decade for most, if not all, patients prescribed local or locoregional radiation therapy 
after breast conservation surgery or mastectomy. Most recently, long term outcome data for 
a 5-fraction schedule delivered by once-weekly treatments has been reported which suggests 
further scope for simplifying curative radiotherapy for women with early breast cancer.    
 
Added value of this study 
Fifteen or 16 fractions over 3 to 3.2 weeks are unlikely to represent the limits of this approach, 
called hypofractionation. The FAST-Forward trial shows that 26Gy in 5 fractions of 5.2Gy to 
the conserved breast or post-mastectomy chest wall after primary surgery is non-inferior in 
terms of 5-year ipsilateral local tumour relapse to 40Gy in 15 fractions over 3 weeks within 
an absolute 1.6% non-inferiority margin compared with 2% incidence following 40Gy. The 5-
day schedule causes milder early skin reaction and comparable rates of late adverse effects. 
When mature, a randomised FAST-Forward sub-study will report the safety of the 5-fraction 
regimen for patients prescribed radiotherapy to breast/chest wall combined with axilla and/or 
supraclavicular fossa. 
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Implications of all the available evidence 
FAST-Forward results confirm that 26Gy in 5 fractions is as effective and safe as an 
international standard 15-fraction regimen after primary surgery for early breast cancer. The 
1-week schedule has major benefits compared with 3- or 5-week regimens in terms of 
convenience and cost for patients and for health services globally. 
 
ABSTRACT  
Background 
FAST-Forward aims to identify a 5-fraction (Fr) schedule of adjuvant radiotherapy (radiation 
therapy) delivered in 1 week which is non-inferior for local cancer control and as safe as an 
international standard 15Fr regimen after primary surgery for early breast cancer. Five-year 
results are presented.  
Methods 
FAST-Forward (ISRCTN19906132) is a non-inferiority randomised controlled trial that 
allocated (1:1:1) patients with invasive carcinoma of the breast (pT1-3 pN0-1 M0) after breast 
conservation surgery or mastectomy to 40Gy in 15Fr (3 weeks), 27Gy or 26Gy in 5Fr (1 week) 
to whole breast/chest wall. Allocation was not blinded due to the nature of the intervention. 
Primary endpoint was ipsilateral breast tumour relapse (IBTR); assuming 2% 5-year 
incidence for 40Gy, non-inferiority was pre-defined as <1.6% excess for 5Fr schedules 
(critical hazard ratio HR=1.81). Normal tissue effects (NTE) were assessed by clinicians, 
patients and photographs.  
Findings 
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4096 consenting patients (1361 40Gy, 1367 27Gy, 1368 26Gy) were recruited November 
2011-June 2014 from 97 UK centres. At 71 months median follow-up, 79 IBTR events were 
reported (40Gy: 31, 27Gy: 27, 26Gy: 21); HRs (95%CI) versus 40Gy/15Fr were 27Gy/5Fr: 
0.86 (0.51,1.44), 26Gy/5Fr: 0.67 (0.38,1.16). Five-year incidence of IBTR after 40Gy was 
2.1% (1.4,3.1); estimated absolute differences versus 40Gy/15Fr were -0.3% (-1.0,0.9) for 
27Gy/5Fr (probability of incorrectly accepting an inferior 5-fraction schedule versus 
40Gy/15Fr, p=0.0022) and -0.7% (-1.3,0.3) for 26Gy/5Fr (p=0.00019 versus 40Gy/15Fr). 
5-year prevalence of any clinician-assessed moderate/marked breast NTE after 40Gy: 
98/986 (10%), 27Gy: 155/1005 (15%), 26Gy: 121/1020 (12%). Across all clinician 
assessments from 1-5 years, odds ratios versus 40Gy/15Fr were 1.55 (1.32,1.83, p<0.0001) 
for 27Gy/5Fr and 1.12 (0.94,1.34, p=0.20) for 26Gy/5Fr. Patient and photographic 
assessments showed higher NTE risk for 27Gy versus 40Gy but not for 26Gy. 
Interpretation 
26Gy/5Fr in 1 week is non-inferior to 40Gy/15Fr in 3 weeks for local tumour control and as 
safe in terms of NTE up to 5 years for patients prescribed adjuvant local radiotherapy after 
primary surgery for early stage breast cancer. 
Funding  
National Institute for Health Research-Health Technology Assessment Programme 
 
BACKGROUND 
The Early Breast Cancer Trialists’ Collaborative Group systematic overview confirms that 
radiotherapy after primary surgery in women with early stage cancers reduces locoregional 
cancer recurrence and breast cancer deaths, including patients with positive lymph nodes 
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treated by mastectomy and axillary clearance1,2. For many decades, schedules of adjuvant 
radiotherapy for these patients delivered 25 fractions of 2Gy in 5 weeks. Randomised 
controlled trials with long-term follow-up have since confirmed that fewer, larger fractions 
giving a lower total dose are at least as safe and effective as the previously-used international 
standard3-10. Specifically, mature data confirm the safety and non-inferiority of 15 or 16 
fractions of ~2.7Gy to total doses of 40.0Gy or 42.5Gy, respectively5,8. A 3-week schedule of 
15 fractions has been the UK standard of care for adjuvant locoregional radiotherapy for early 
breast cancer since 2009 and is now an international standard for adjuvant local 
radiotherapy11,12. There is no reason to assume that 15 fractions represent the lower limits of 
this hypofractionated and accelerated approach. We report outcomes of a randomised phase 
III trial testing 2 dose levels of a 5-fraction regimen delivered in 1 week against 40Gy in 15 
fractions in 3 weeks for patients prescribed local radiotherapy after breast conservation 
surgery or mastectomy for early breast cancer. The objectives are to identify a 1-week 
schedule non-inferior to a standard 3-week regimen for 5-year local tumour control and 
comparable in terms of late adverse effects. FAST-Forward was informed by the FAST trial 
that tested 2 dose levels of 5 once-weekly fractions13,14; FAST trial results to 10-year follow-
up are in press. The trial design used dose levels estimated to be the upper and lower bounds 
isoeffective with the control schedule in terms of tumour control and normal tissue effects. 
 
METHODS 
Study design 
FAST-Forward (https://www.icr.ac.uk/fastforward (last accessed 07/04/2020); protocol in 
appendix) is a multicentre, non-blinded phase III randomised controlled non-inferiority trial 
testing the safety and efficacy of 5-fraction (Fr) schedules of adjuvant radiotherapy to the 
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whole breast/chest wall delivered in one week compared with the UK standard 15-fraction 
schedule. Sub-studies included a published acute toxicity study15, photographic assessments 
of late adverse effects and patient-reported outcomes (PRO); not all centres participated in 
the sub-studies. Following recruitment into the main trial a further sub-study opened testing 
the same fractionation schedules for patients requiring radiotherapy to the axilla and/or 
supraclavicular fossa (SCF) lymph nodes after sentinel node biopsy or SCF only (levels 3-4) 
after axillary dissection with a primary endpoint focussing on safety. Patients and results from 
this sub-study are not reported here since follow-up is not mature. FAST-Forward was 
approved by the national South East Coast Kent Research Ethics Committee (11/LO/0958) 
and local Research and Development offices of all participating centres. The trial was 
sponsored by The Institute of Cancer Research and is registered as ISRCTN19906132. All 
patients provided written informed consent. 
 
Patients 
Eligible patients were women or men aged >18 years with invasive carcinoma of the breast 
(pT1-3 pN0-1 M0) following complete microscopic excision of primary tumour by breast 
conservation surgery or mastectomy (reconstruction allowed), recruited in the UK from 47 
radiotherapy centres and 50 referral centres. A protocol amendment in February 2013 
excluded the lowest risk patients (aged ≥65 years pT1 G1/G2 ER+ HER2- pN0 M0) to 
increase the overall primary event rate. All patients had axillary surgery (sentinel node biopsy 
and/or axillary dissection); nodal radiotherapy was not allowed in the main study. Concurrent 
endocrine therapy and/or trastuzumab were permitted but not concurrent chemotherapy. For 
the PRO sub-study all patients at participating centres were eligible. All patients who had 
breast conservation surgery were eligible for the photographic sub-study at participating 
centres. A small number of post-mastectomy patients were recruited into the photographic 
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sub-study to validate the scoring method in chest wall patients but are not reported here as 
photographs were only available for 76 patients.   
 
Randomisation and masking 
Patients were randomised (1:1:1) to receive 40Gy in 15 fractions of 2.67Gy, 27Gy in 5 
fractions of 5.4Gy or 26Gy in 5 fractions of 5.2Gy. A sequential tumour bed radiotherapy 
boost to the conserved breast was allowed, with centres required to specify boost intention 
and dose (10Gy or 16Gy in 2Gy fractions) before randomisation. Randomisation was 
performed by telephone or fax from the recruiting centre to the Clinical Trials and Statistics 
Unit, Institute of Cancer Research (ICR-CTSU), London, and used an in-house bespoke trial-
specific randomisation system set-up by the ICR-CTSU IT team. Computer-generated 
random permuted blocks were used (block sizes 6 and 9), stratified by radiotherapy centre 
and risk group (high: age <50 years or grade 3 versus low: age ≥50 years and grade 1 or 2). 
Treatment allocation was not blinded to clinicians or patients.  
Test dose levels were informed by START and FAST trials generating α/β values for late 
normal tissue effects (NTE)8,15. Assuming α/β=3Gy and no effect of overall time on outcomes, 
27Gy/5Fr of 5.4Gy was predicted to match late NTE of 40Gy/15Fr of 2.7Gy or 46Gy/23Fr of 
2Gy. Allowance for a possible effect of treatment time informed the choice of the slightly lower 
26Gy dose level.  
 
Radiotherapy 
The whole breast clinical target volume (CTV) including the soft tissues from 5mm below the 
skin surface to the deep fascia was either determined from field-based tangential fields or 
volumed prospectively. Post-mastectomy chest wall CTV encompassed post-surgical skin 
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flaps and underlying soft tissues to the deep fascia; both excluded underlying muscle and rib 
cage. Surgeons were strongly encouraged to mark the tumour cavity walls with titanium clips 
or gold seeds at the time of breast conservation surgery in order to aid placement of tangential 
fields and delineation of tumour bed. A typical margin of 10mm was added around the 
breast/chest wall CTV accounting for set-up error, breast swelling and breathing to create a 
planning target volume (PTV). For all patients a full 3D CT set of outlines covering the whole 
breast and organs at risk was collected with a slice separation up to 5mm and organs at risk 
were outlined prospectively. A tangential opposing pair beam arrangement encompassed the 
whole breast/chest wall PTV, minimising the ipsilateral lung and heart exposure. The 
treatment plan was optimised with 3D dose compensation to achieve the following PTV dose 
distribution: >95% received 95% of prescribed dose, <5% received ≥105%, <2% received 
≥107% and global maximum <110%. Dose constraints for the control group were: volume of 
ipsilateral lung receiving 12Gy <15%, and volume of heart receiving 2Gy and 10Gy <30% 
and <5% respectively. Dose constraints for the 5-fraction schedules were: volume of 
ipsilateral lung receiving 8Gy <15%, and volume of heart receiving 1.5Gy and 7Gy <30% and 
<5% respectively. X-ray beam energies for treatment were 6 megavoltage (MV) or 10MV, but 
a mixture of energies e.g. 6MV and 10-15MV was allowed for larger patients. Tumour bed 
boost was delivered via electrons or photons. Verification was carried out using electronic 
portal imaging using MV or kV x-rays. Control group treatment verification was required for 
at least 3 fractions in the first week with correction for any systematic error and then once 
weekly with a tolerance of 5mm. The 5-fraction schedules required verification imaging for 
each fraction with recommendations to correct all measured displacements. A 
comprehensive quality assurance programme involved every radiotherapy centre before trial 
activation and continued throughout trial accrual; this was co-ordinated by the UK 
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Radiotherapy Trials Quality Assurance team based at Mount Vernon Hospital, UK. The 
radiotherapy planning pack is in the appendix. 
 
Assessments 
Patients were assessed by clinicians for ipsilateral breast tumour relapse (IBTR) and late 
NTE at annual follow-up visits. Starting 12 months after trial entry, late-onset NTE in ipsilateral 
breast/chest wall (breast distortion, shrinkage, induration and telangiectasia; breast/chest 
wall oedema and discomfort) were graded by clinicians on a 4-point scale (none, a little, quite 
a bit or very much), interpreted as none, mild, moderate or marked. Symptomatic rib fracture, 
symptomatic lung fibrosis and ischaemic heart disease were recorded. Clinical assessments 
of acute skin toxicity have been previously reported15. 
 
In the PRO sub-study, questionnaires were administered at baseline (pre-randomisation), 3, 
6, 12, 24 and 60 months, including the European Organisation for Research and Treatment 
of Cancer (EORTC) QLQ-BR23 breast cancer module, body image scale and protocol-
specific questions relating to changes to affected breast following treatment (including breast 
appearance changed, smaller, harder/firmer, skin appearance changed). Patient 
assessments used a 4-point scale (not at all, a little, quite a bit, very much).  
 
In the photographic sub-study, photographs were taken at baseline, 2 and 5 years after 
radiotherapy. Change in photographic breast appearance compared with the post-surgical 
(pre-radiotherapy) baseline was scored on a 3-point scale (none, mild or marked) based on 
changes in breast size and shape relative to the contralateral breast. Patients were ineligible 
for further photographic assessments following breast reconstruction surgery and further 
ipsilateral disease. Digital photographs were scored by three observers blind to patient 
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identity and treatment allocation following scoring procedures established in the START 
trials16. Breast size and surgical deficit were assessed from the baseline photographs on a 
3-point scale (small, medium, large).  
 
Outcomes 
The primary endpoint was IBTR, defined as invasive carcinoma or ductal carcinoma in situ 
presenting anywhere in the ipsilateral breast parenchyma and/or overlying skin or post-
mastectomy chest wall whether considered local recurrence or new primary tumour. Data on 
first regional relapse (axilla, supraclavicular fossa and internal mammary chain), distant 
metastases, new primary cancer and death were collected. Key secondary endpoints were 
late NTE assessed by clinicians, patients and from photographs, and other disease-related 
and survival outcomes.  
 
Statistical considerations 
The target sample size was 4000 patients (balanced allocation between groups). This 
provided 80% power (1-sided α=0.025 allowing for non-inferiority hypothesis and a simple 
Bonferroni correction taking into account comparisons between each test schedule and the 
control group17) to exclude an absolute increase of 1.6% in 5-year IBTR incidence for a 5-
fraction schedule compared with control, assuming 2% 5-year incidence in the 40Gy group 
(START data7 and allowing for reduced IBTR due to evolution of surgical techniques and 
systemic therapy). The 1.6% absolute non-inferiority margin was defined at the trial design 
stage by the protocol development group that included clinicians and patient advocates, and 
was considered to be acceptable and appropriate. Binary proportions were used for the 
sample size calculations as event rates are so low. Estimates allowed for 10% loss to follow-
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up or unevaluable, expected to be largely due to development of metastatic disease. 2196 
patients (732 per group) was estimated for the photographic and PRO sub-studies to provide 
80% power to detect an 8% difference in the 5-year prevalence of late NTE between the 5-
fraction schedules (assuming 35% with 5-year mild/marked change in photographic breast 
appearance from START-B 40Gy results7), allowing for 10% loss to follow-up or unevaluable.  
 
Kaplan-Meier estimates (with 95% confidence intervals, CI) of 5-year IBTR incidence were 
calculated, and hazard ratios (HR, 95%CI) comparing fractionation schedules obtained from 
Cox proportional hazards (PH) regression, censoring patients at date of death or last follow-
up. Absolute differences (95%CI) in 5-year IBTR incidence were estimated by applying the 
HRs (and CI) to the control group 5-year event-free estimate18. Primary assessment of non-
inferiority was based on whether the upper limit of the 2-sided 95%CI (corresponding to 1-
sided 97.5%CI) for the absolute difference in 5-year IBTR was <1.6%. Non-inferiority of each 
5-fraction schedule versus control was also tested using the a priori critical HR of 1.81 
(ln0.964/ln0.98, from protocol-specified incidence); p<0.025 was deemed statistically 
significant (probability of incorrectly accepting an inferior 5-fraction schedule). An exploratory 
competing risks analysis was done for IBTR, with death from any cause as a competing event 
in a Fine-Gray competing risks regression model. 
 
Clinician and patient assessments of late NTE were analysed as follows: (i) 5-year cross-
sectional analyses compared prevalence of moderate/marked effects versus none/mild 
between groups using risk ratios and risk differences (95%CI), and Fisher’s exact test; (ii) 
longitudinal analyses of moderate/marked effects (versus none/mild) using generalised 
estimating equations (GEE)19 including all assessments, comparing groups across the whole 
follow-up period using odds ratios (OR, 95%CI) and the Wald test; GEE models included a 
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term representing years of follow-up, enabling time trends to be modelled. Additionally, to 
enable comparison of clinician-assessed NTE with results reported from other trials, survival 
analysis methods analysed time to first moderate/marked event, including Kaplan-Meier 
estimates of cumulative incidence, and groups compared using HR (95%CI) from Cox PH 
regression and the pairwise log-rank test.  
 
Scores for change in photographic breast appearance at 2 and 5 years were modelled using 
GEE. Categories of mild and marked change in photographic breast appearance were 
combined for analysis as there were very few with marked change. Pairwise comparisons of 
mild/marked change at 2 and/or 5 years between groups were described by OR (95%CI) 
obtained from the GEE models and the Wald test.  Due to multiple testing a significance level 
of 0.005 was used for the clinician and patient NTE assessments; all hypotheses for the NTE 
endpoints were 2-sided. 
 
Estimates of fractionation sensitivity (α/β values, 95%CI) in FAST-Forward were obtained for 
the primary endpoint of IBTR and late NTE as per methodology in the START and FAST 
trials3. The α/β estimate for breast cancer was obtained from a Cox PH regression model of 
time to first IBTR, and for late NTE from GEE models including all follow-up assessments 
(separate models for photographic and clinician assessments). Each model included terms 
for total dose and total dose multiplied by fraction size; the α/β ratio was calculated by dividing 
the 2 parameter estimates respectively, with a 95%CI estimated from the model using the 
covariance of the two estimates (lower confidence limits were truncated at zero). Isoeffect 
doses in 2Gy equivalents (EQD2) were calculated for the 5-fraction schedules, together with 
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an estimate of the 5-fraction schedule isoeffective with 40Gy in 15 fractions in terms of local 
tumour control and late NTE. No correction was made for difference in treatment time. 
 
There were no formal interim analyses; accumulating data were monitored annually by the 
Independent Data Monitoring Committee. All analyses were performed on an intention-to-
treat basis that included all patients according to their allocated treatment regardless of what 
was actually received. As the main hypothesis was non-inferiority the primary endpoint was 
also tested in the per protocol population, which excluded patients for whom a major deviation 
was reported. The database snapshot was taken on 22/11/2019; Stata version 15 
(StataCorp) was used for analyses. 
 
Role of the funding source 
The funding source provided peer-reviewed approval for the trial but had no role in study 
design, collection, analysis, interpretation of data, or writing the report. The corresponding 
author had full access to all trial data and had final responsibility for the decision to submit 
for publication. 
 
 
RESULTS 
Between November 2011 and June 2014, 4110 patients were enrolled in the FAST-Forward 
trial. Fourteen withdrew consent for use of data and were removed from the intention-to-treat 
population; hence results are reported for 4096 consenting participants. Nine patients were 
found to be ineligible after randomisation; 3 in the control group received 40Gy in 15 fractions 
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as standard and 6 in the test groups did not receive the allocated schedule. Twenty eligible 
patients received a non-allocated schedule, and 6 received no radiotherapy. Compliance with 
allocated treatment was 99% (Figure 1). Demographic and clinical characteristics at baseline 
were well-balanced between groups (Table 1). Overall, 2551/4096 (62%) were classified as 
low risk (age >50 and grade 1 or 2); the majority were ER positive/HER2 negative (3335/4077 
with data, 82%), and 407/4077 with data (10%) were HER2 positive. 3832 (93%) had breast 
conservation surgery, 1011 (25%) received a radiotherapy boost to tumour bed, 1174 (29%) 
had neo- or adjuvant chemotherapy, 3512/3649 (96%) ER positive patients had endocrine 
therapy, and 311/407 (76%) HER2 positive patients received trastuzumab. Five-year visit 
forms were available for 3563 (93%) patients out of 3830 still in follow-up (not died, withdrawn 
or lost). 
 
After a median follow-up of 71.5 months (IQR 71.3, 71.7), IBTR was recorded in 79 patients 
(40Gy: 31, 27Gy: 27, 26Gy: 21). Estimated cumulative incidence of IBTR up to five years was 
2.1% (95%CI 1.4, 3.1) for 40Gy (expected incidence 2%), 1.7% (1.2, 2.6) for 27Gy and 1.4% 
(0.9, 2.2) for 26Gy (Table 2, Figure 2). Estimated absolute differences in IBTR versus 40Gy 
were -0.3% (-1.0, 0.9) for 27Gy and -0.7% (-1.3, 0.3) for 26Gy. Since the upper confidence 
limits excluded an increase in IBTR of >1.6%, non-inferiority can be claimed for both 5-
fraction schedules compared with 40Gy in 15 fractions. This is confirmed by a test against 
the critical HR>1.81, with p=0.0022 for 27Gy and p=0.00019 for 26Gy compared with 40Gy. 
Analyses in the per protocol population were consistent (estimated absolute difference versus 
40Gy -0.4%; (-1.0,0.8), p=0.0017 for 27Gy and -0.6% (-1.2,0.4), p=0.00037 for 26Gy; full 
data for per-protocol analyses not shown as 99% treatment compliance). Comparing the 5-
fraction schedules, the estimated absolute difference in IBTR cumulative incidence up to five 
years was -0.4% (-1.0, 0.6) for 26Gy versus 27Gy. The unadjusted α/β estimate for IBTR was 
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3.7Gy (0.3, 7.1Gy), with EQD2 estimates of 44.7Gy for 40Gy, 43.1Gy for 27Gy and 40.6Gy 
for 26Gy with no correction for treatment time. Adjusting for risk group and ER/HER2 status 
made minimal difference (adjusted α/β estimate 3.7Gy; 0.4, 6.9). Hazard ratios obtained from 
a competing risks analysis of IBTR with death from any cause as a competing event were 
almost identical to those from the primary analysis reported in Table 2 (HRs from competing 
risks model: 0.85 (95%CI 0.51, 1.43) for 27Gy versus 40Gy; 0.67 (0.38, 1.16) for 26Gy versus 
40Gy). 
 
Regional relapses occurred in 34/4096 (1%) patients (40Gy: 13, 27Gy: 11, 26Gy: 10; Table 
3), 6 of which were concurrent with IBTR. Incidence of locoregional relapse, distant relapse, 
disease-free and overall survival were similar between groups, with no statistically significant 
differences (Table 2, Figures A1 and A2). No formal subgroup analyses were done due to 
the low number of primary events, but frequencies of IBTR, regional and distant relapse were 
tabulated according to age, grade and ER/HER2 status for descriptive purposes; as 
expected, there were more IBTR in the patients with higher grade primary tumours (Table 
A1). Invasive contralateral breast cancer was reported for 55/4096 (1%) patients (40Gy: 18, 
27Gy: 17, 26Gy: 20; Table 3), and non-breast second primary cancers for 123/4096 (3%) 
patients (40Gy: 42, 27Gy: 37, 26Gy: 44; Table 3), the most common being colorectal cancer 
with 25 cases in total. 
 
A total of 287/4096 (7%) patients died, 151 (4%) from breast cancer, 125 (3%) from other 
causes (including 38 (1%) from second cancers and 27 (1%) cardiac-related), and 11 (0.3%) 
with unknown cause of death and no evidence of disease relapse (Table 3). Of 27 patients 
with a cardiac-related death (40Gy: 10, 27Gy: 9, 26Gy: 8), 15 (40Gy: 7, 27Gy; 4, 26Gy: 4) 
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had a history of cardiac disease reported at randomisation or was a current/ex-smoker in past 
year.  
 
At least one annual clinical assessment of NTE was available for 3975/4096 (97%) patients. 
At 5 years, any moderate/marked clinician-assessed NTE in the breast/chest wall was 
reported for 98/986 (10%) patients in the 40Gy group, 155/1005 (15%) for 27Gy and 
121/1020 (12%) for 26Gy (Table A2, Figure A3), with a statistically significant difference 
between 40Gy and 27Gy (p=0.0003) but not between 40Gy and 26Gy (p=0.17). Breast 
shrinkage was the most prevalent moderate/marked effect at 5 years, reported in 50/916 
(6%) for 40Gy, 78/948 (8%) for 27Gy and 65/954 (7%) for 26Gy (Table A2).  Longitudinal 
analysis of all annual clinical assessments of NTE over follow-up showed a statistically 
significant increased risk of any moderate/marked effect in the breast/chest wall for the 27Gy 
group compared with 40Gy (OR 1.55; 1.32, 1.83; p<0.0001), with no statistically significant 
difference between 26Gy and 40Gy (OR 1.12; 0.94, 1.34; p=0.20); Table 4. This pattern was 
similar for the individual effects of breast distortion, shrinkage, induration and breast/chest 
wall oedema, with statistically significant higher risk for 27Gy compared with 40Gy but not for 
26Gy (Table 4, Figure A3). Comparing the two 5-fraction schedules, 26Gy had statistically 
significantly lower risk of any moderate/marked breast/chest wall NTE (p=0.0001) and breast 
shrinkage (p=0.0018) compared with 27Gy. Estimates of 5-year cumulative incidence of any 
moderate/marked clinician-assessed NTE in the breast/chest wall were 26.8% (95%CI 24.4, 
29.4) for 40Gy, 35.1% (32.4, 37.9) for 27Gy and 28.5% (26.0, 31.1) for 26Gy (Table A3). 
Results for comparison of schedules from the analyses of time to first moderate/marked effect 
were similar to those from the longitudinal modelling of all annual clinical assessments (Table 
A3).  
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1796 patients consented to the PRO sub-study, 18 of whom withdrew consent immediately 
after randomisation or were not given the baseline booklet. Questionnaires returned from 
those expected (patients alive and well, not withdrawn) totalled 1771/1778 (99%) at baseline, 
1668/1733 (96%) at three months, 1622/1722 (94%) at six months, 1599/1707 (94%) at one 
year, 1531/1669 (92%) at two years and 1334/1589 (84%) at five years. Of the 1774 patients 
with at least one completed questionnaire, 1634 had breast conservation surgery and 140 
mastectomy. Change in breast appearance had the highest 5-year prevalence, with 
moderate/marked change reported in 140/432 (32%) for 40Gy, 158/440 (36%) for 27Gy and 
136/429 (32%) for 26Gy. There were no statistically significant differences in 5-year 
prevalence of patient-reported adverse effects between the schedules (Table A4, Figure A3). 
There was some evidence of an increase in patient-reported moderate/marked breast 
hardness/firmness at 5 years for 27Gy compared with 40Gy and more breast swelling in both 
5-fraction schedules, but these were not statistically significant at the pre-specified cut-off of 
p=0.005. Longitudinal analyses of all patient assessments from baseline to 5 years showed 
a statistically significantly higher risk of moderate/marked breast hardness/firmness for 27Gy 
compared with 40Gy (OR 1.42, 1.17, 1.72, p=0.0003), and less change in breast appearance 
for 26Gy compared with 27Gy (p=0.0018), but no statistically significant differences between 
schedules for the other NTE (Table 5, Figure A3).  
 
Of the 1737 patients (breast conservation surgery and post-mastectomy) who consented to 
the photographic sub-study, baseline photographs were received for 1634 (94%), and 2 
and/or 5-year photographs were available for 1385 (80%). The vast majority (1309) were 
patients who had breast conservation surgery; for these patients, 2 and 5-year photographs 
were assessed in 1267 and 875 respectively (Table A5). A total of 226 patients died or 
withdrew from the photographic sub-study by year 5, for the remainder the most common 
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reasons for photographs not being taken were appointments not made due to clerical errors 
at the centres, patients not attending clinic visits, and patients withdrawing consent from the 
sub-study. At 2 years, mild/marked change in photographic breast appearance was reported 
in 35/411 (8%) for 40Gy, 67/429 (16%) for 27Gy and 46/427 (11%) for 26Gy; corresponding 
figures at 5 years were 34/283 (12%) for 40Gy, 83/308 (27%) for 27Gy and 37/284 (13%) for 
26Gy (Table A5). Modelling 2- and 5-year photographic assessments together, 27Gy had a 
statistically significantly increased risk of mild/marked change in breast appearance 
compared with 40Gy (OR 2.29; 1.60, 3.27; p<0.0001), with no statistically significant 
difference between 26Gy and 40Gy (OR 1.26; 0.85, 1.86; p=0.24; Table A5). 26Gy had a 
statistically significantly lower risk of change in photographic breast appearance compared 
with 27Gy (p=0.0006). 
 
The unadjusted α/β estimate for any moderate/marked clinician-assessed NTE in the 
breast/chest wall was 1.7Gy (1.2, 2.3), giving EQD2 estimates of 47.1Gy for 40Gy/15Fr, 
51.6Gy for 27Gy/5Fr and 48.3Gy for 26Gy/5Fr; adjusting for prognostic factors (age, boost, 
whole-breast planning treatment volume as a proxy for breast size) made very little 
difference. α/β estimated from the photographic endpoint (adjusting for breast size and 
surgical deficit evaluated from the baseline photographs) was very similar (1.8Gy; 1.1, 2.4). 
The unadjusted α/β estimate for patient-reported change in breast appearance was 2.3Gy 
(1.8, 2.9), resulting in EQD2 estimates of 46.1Gy, 48.2Gy and 45.2Gy for the 40Gy, 27Gy and 
26Gy schedules respectively; as above, adjusting for covariates made minimal difference.  
 
The most common specialist referral for radiotherapy-related adverse effects during follow-
up was to lymphoedema clinics (Table A6). Incidence of ischaemic heart disease, 
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symptomatic rib fracture and symptomatic lung fibrosis was very low at this stage of follow-
up (Table A7). 
 
DISCUSSION 
Non-inferiority in terms of IBTR of 5-fraction schedules compared with 40Gy in 15 fractions 
is demonstrated at 5 years’ follow-up for patients with early breast cancer, the majority of 
whom were treated by local tumour excision and sentinel node biopsy for node negative 
disease. NTE up to 5 years for 26Gy in 5 fractions were comparable with 40Gy in 15 fractions. 
Extremely low rates of IBTR and of moderate/marked late NTE can be attributed to 
improvements in all diagnostic and treatment modalities and to the commitment of patients 
to early diagnosis and randomised trials20. 
 
The 10-year analyses of IBTR and NTE reported by earlier Canadian and UK trials confirm 
that although NTE continue to accumulate beyond 5 years, there is evidence that relative 
differences between test and control groups change very little over time3-8,21. In START-B 
trial, the hazard ratio (95%CI) for clinician-assessed breast shrinkage after 40Gy in 15 
fractions compared with 50Gy in 25 fractions was 0.83 (0.66-1.04) at 5 years and 0.80 (0.67-
0.96) at 10 years, by which time the proportion of patients with breast shrinkage increased 
from 11.4% (9.5-13.6) at 5 years to 26.2% (23.2-29.6)8. The findings of FAST-Forward can 
be applied to different prognostic groups in view of the very low overall IBTR incidence, a 
conclusion consistent with meta-analysis of 5861 patients entered into the three START trials, 
which identified no inconsistency of effect in terms of NTE or recurrence risk across any of 
the prognostic or treatment subgroups investigated8. 
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The lack of a detectable dose response for local tumour control between 26Gy and 27Gy in 
5 fractions is a potential limit to precision, but this feature reflects the shallowness of the dose 
response curve for subclinical breast cancer around the 98% control level, so the -0.4% 
estimated difference in absolute levels of IBTR between 27Gy and 26Gy likely reflects 
random sampling variability in the IBTR rate and/or chance imbalances in unmeasured 
prognostic factors between test groups. For late NTE the dose response is much steeper, 
enabling detection of clinically and statistically significant differences in event rates between 
26Gy and 27Gy in 5 fractions. The 5-fraction schedule isoeffective with 40Gy in 15 fractions 
allows direct estimation of α/β for late NTE, which is consistent with values generated from 
our other trials. The α/β value of 3.7Gy (0.3-7.1) for tumour control in FAST-Forward is similar 
to 3.5Gy (1.2–5.7) estimated from the START pilot and START-A trials8.  Point estimates of 
α/β, assuming no effect of time, for late NTE in FAST-Forward scored by clinicians, patients 
and photographic assessments are closer to 2Gy than the 3Gy estimated in the earlier 
START8 and FAST trials14, but 95%CI overlap for each endpoint in all trials. In FAST, 915 
women were randomised after breast conservation surgery for node negative disease to 
50Gy in 25 fractions versus 2 dose levels of a 5-fraction regimen delivered once-weekly, 
thereby ensuring complete repair between fractions and controlling for overall treatment 
time13,14. The α/β value for change in photographic breast appearance in FAST was 2.6Gy 
(1.4–3.7). Uncertainty about biological processes, which include a time factor in FAST-
Forward, does not interfere with clinical evaluation and decisions on implementation of FAST-
Forward results in comparable patient groups. 
 
The 5-fraction regimen is relevant to partial breast radiotherapy, the preferred alternative to 
whole breast radiotherapy for many women after recent phase III trials22-25. Beyond its safety 
and effectiveness, the 26Gy FAST-Forward schedule is convenient and substantially less 
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expensive for patients and for health services. It is also likely to be safe for patients requiring 
regional radiotherapy, an approach currently under formal evaluation in a randomised FAST-
Forward sub-study comparing 40Gy in 15 fractions and 26Gy in 5 fractions. Assuming no 
effect of time, 26Gy in 5 fractions is equivalent to 46.8Gy and 53.7Gy in 2Gy fractions 
assuming α/β values 2 and 1Gy, respectively, dose intensities well within the limits of 
tolerance for these structures26,27. Finally, there is no reason to consider the heart more 
sensitive to fraction size than most other soft tissues, but it is undoubtedly sensitive to total 
dose28. Any heart exposure is potentially harmful, so the priority is to exclude the heart from 
the treatment volume as far as possible using deep inspiration breath hold or comparable 
technique29,30. 
 
In conclusion, 5-year IBTR incidence after a 1-week course of adjuvant breast radiotherapy 
delivered in 5 fractions is non-inferior to the standard 3-week schedule according to the pre-
defined inferiority threshold. The 26Gy dose level is comparable to 40Gy in 15 fractions in 
terms of patient-assessed NTE, clinician-assessed NTE, and photographic change in breast 
appearance, and is comparable to NTE expected after 46-48Gy in 2Gy fractions. The 
consistency of FAST-Forward results with earlier hypofractionation trials supports the 
adoption of 26Gy in 5 daily fractions as a new standard for women with operable breast 
cancer requiring adjuvant radiotherapy to partial or whole breast. 
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Figure 2: Cumulative risk of ipsilateral breast tumour relapse by fractionation schedule 
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Figure 1: FAST-Forward Trial profile  
 
 
 
 
7 did not receive  
allocated therapy 
 
2 patient choice (1 no 
radiotherapy, 1 given 27Gy 
in 5Fr); 
2 treatment prolonged due to 
patient illness; 
3 treatment stopped early (2 
after 12Fr, 1 after 2Fr due to 
patients unwilling to 
continue) 
1361 patients allocated to  
40Gy in 15 Fr (3 weeks) 
 
1368 patients allocated to  
26Gy in 5 Fr (1 week) 
1367 patients allocated to  
27Gy in 5 Fr (1 week) 
4096 patients randomised1 
1354 patients received allocated therapy 
 
1347 patients received allocated therapy 
 
1355 patients received allocated therapy 
 
1 14 patients withdrew consent for any of their data to be used in the analysis (7 x 40Gy, 3 x 27Gy, 4 x 26Gy); 2 1 no radiotherapy given as patient unable to get into stable position for RT; 3 
given 40Gy in 15Fr: 1 concern for brachial plexus, 1 decided on different treatment plan, 1 constraints of treatment planning); 3 1 no radiotherapy given as patient diagnosed with 
pemphigoid; 8 given 40Gy in 15Fr: 1 dose constraints not met, 1 unable to plan within protocol constraints due to tumour bed position, 1 poor PTV coverage, 1 technical difficulties in 
planning, 1 transferred to direct electron field, 1 simulator plan as 3D images not possible, 1 small pericardial effusion found at planning, 1 reason not given) 
 
1361 patients included in analysis 
 
 
1368 patients included in analysis 
 
 
1367 patients included in analysis 
 
 
12 did not receive 
allocated therapy 
 
2 ineligible (1 recurrence 
detected after recruitment so 
radiotherapy cancelled, 1 
tissue expander in situ); 
4 patient choice (3 no 
radiotherapy, 1 given 40Gy 
in 15Fr); 
4 investigator decision2 (1 no 
radiotherapy, 3 given 40Gy 
in 15Fr); 
1 withdrawal of consent; 
1 site error (patient given 
26Gy in 5Fr) 
21 did not receive 
allocated therapy 
 
4 ineligible (3 metastases 
detected before start of 
radiotherapy, 1 previous 
DCIS in contralateral breast); 
6 patient choice (given 40Gy 
in 15Fr); 
9 investigator decision3 (1 no 
radiotherapy, 8 given 40Gy 
in 15Fr); 
2 treatment stopped early (1 
after 1 Fr as patient admitted 
to hospital with pneumonia, 
1 patient unwilling to 
continue) 
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Figure 2: Cumulative risk of ipsilateral breast tumour relapse by fractionation 
schedule 
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Table 1: Demographic, clinical and treatment characteristics at randomisation of the 
4096 patients consenting to the FAST-Forward trial1 
  
40 Gy / 15 Fr 
N=1361 (%) 
27 Gy / 5 Fr 
N=1367 (%) 
26 Gy / 5 Fr 
N=1368 (%) 
Age (years)       
Median (IQR) 60 (53-66) 61 (53-67) 61 (52-66) 
[range] 29-89 25-90 25-89 
      
<40 12 (0.9) 16 (1.2) 28 (2.0) 
40-49 186 (13.7) 173 (12.7) 189 (13.8) 
50-59 440 (32.3) 423 (30.9) 414 (30.3) 
60-69 506 (37.2) 511 (37.4) 524 (38.3) 
70-79 175 (12.9) 197 (14.4) 172 (12.6) 
>80 42 (3.1) 47 (3.4) 41 (3.0) 
Sex    
Female 1355 (99.6) 1365 (99.9) 1362 (99.7) 
Male 6 (0.4) 2 (0.1) 4 (0.3) 
Not known 0 0 2 
Tumour grade       
1 315 (23.1) 315 (23.0) 300 (21.9) 
2 660 (48.5) 663 (48.5) 690 (50.4) 
3 386 (28.4) 389 (28.5) 378 (27.6) 
Risk group      
Low (age ≥50 & grade 1 or 2) 843 (61.9) 854 (62.5) 854 (62.4) 
High (age <50 and/or grade 3) 518 (38.1) 513 (37.5) 514 (37.6) 
Primary surgery    
Breast conservation surgery 1270 (93.3) 1278 (93.5) 1284 (93.9) 
BCS with oncoplastic technique 42 33 42 
    
Mastectomy 91 (6.7) 89 (6.5) 84 (6.1) 
 Mastectomy with immediate reconstruction 8 11 7 
Type of reconstruction (mastectomy 
patients): 
   
Autologous reconstruction 5 7 3 
Implant-based reconstruction 2 4 4 
Reconstruction type not specified 1 0 0 
Side of primary    
Left 726 (53.3) 674 (49.3) 662 (48.5) 
Right 635 (46.7) 693 (50.7) 704 (51.5) 
Not known 0 0 2 
Maximal extent of axillary staging       
Sentinel node biopsy/guided axillary 
sampling 
1157 (85.0) 1184 (86.6) 1164 (85.2) 
Axillary clearance 200 (14.7) 181 (13.2) 201 (14.7) 
Other 4 (0.3) 2 (0.1) 1 (0.1) 
Not known  0 0 2 
Pathological node status       
Positive 257 (18.9) 243 (17.8) 256 (18.7) 
Negative 1103 (81.1) 1124 (82.2) 1110 (81.3) 
Not known 1 0 2 
Histological type    
Infiltrating ductal 1084 (79.6) 1096 (80.2) 1086 (79.6) 
Lobular 144 (10.6) 139 (10.2) 127 (9.3) 
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40 Gy / 15 Fr 
N=1361 (%) 
27 Gy / 5 Fr 
N=1367 (%) 
26 Gy / 5 Fr 
N=1368 (%) 
Mixed 51 (3.7) 63 (4.6) 65 (4.8) 
Other 82 (6.0) 69 (5.0) 87 (6.4) 
Not known 0 0 3 
Pathological tumour size (cm)       
Median (IQR) 1.6 (1.1-2.2) 1.6 (1-2.2) 1.6 (1.1-2.4) 
pT stage    
T1mi 4 (0.3) 5 (0.4) 6 (0.4) 
T1a 69 (5.1) 68 (5.0) 51 (3.7) 
T1b 258 (19.0) 270 (19.8) 256 (18.8) 
T1c 612 (45.1) 601 (44.1) 602 (44.1) 
T2 394 (29.0) 389 (28.5) 424 (31.1) 
T3 21 (1.5) 30 (2.2) 25 (1.8) 
Not known 3 4 4 
ER / HER2 status      
ER+ / HER2+ 103 (7.6) 103 (7.6) 93 (6.8) 
ER+ / HER2- 1108 (81.8) 1130 (82.9) 1097 (80.7) 
ER- / HER2+ 32 (2.4) 34 (2.5) 42 (3.1) 
ER- / HER2- 111 (8.2) 96 (7.0) 128 (9.4) 
Not known 7 4 8 
PgR status       
Positive 577 (73.1) 541 (70.3) 566 (69.8) 
Negative 212 (26.9) 229 (29.7) 245 (30.2) 
Not done 571 596 555 
Missing on form 1 1 2 
Lymphovascular invasion      
Present 186 (14.2) 178 (13.7) 202 (15.4) 
Absent 1085 (83.1) 1084 (83.3) 1055 (80.7) 
Uncertain 34 (2.6) 40 (3.1) 51 (3.9) 
Not known 56 65 60 
Neo-adjuvant chemotherapy received       
Yes 48 (3.5) 56 (4.1) 43 (3.1) 
No 1312 (96.5) 1311 (95.9) 1323 (96.9) 
Not known 1 0 2 
Adjuvant therapy received2     
All patients:    
Chemotherapy3 333/1360 (24.5) 324/1367 (23.7) 370/1366 (27.1) 
    
HER2 + patients:    
Trastuzumab 100/135 (74.1) 98/137 (71.5) 113/135 (83.7) 
Chemotherapy & trastuzumab  84 85 100 
Trastuzumab, no chemotherapy 16 13 13 
Chemotherapy, no trastuzumab 2 2 0 
No chemotherapy, no trastuzumab 33 37 22 
    
ER+ patients:    
Endocrine therapy 1169/1216 (96.1) 1186/1237 (95.9) 1157/1196 (96.7) 
Boost given       
Yes 342 (25.2) 337 (24.7) 332 (24.4) 
No 1017 (74.8) 1027 (75.3) 1031 (75.6) 
Not known 2 3 5 
    
Boost dose N=342 N=337 N=332 
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40 Gy / 15 Fr 
N=1361 (%) 
27 Gy / 5 Fr 
N=1367 (%) 
26 Gy / 5 Fr 
N=1368 (%) 
10Gy/5fr 260 (76.0) 273 (81.0) 257 (77.4) 
16Gy/8fr 80 (24.0) 64 (19.0) 75 (22.6) 
Not known 2 0 0 
IQR = interquartile range; BCS = breast conservation surgery 
1 14 patients withdrew consent for any of their data to be used in analysis 
2 Patients could have more than one type of adjuvant systemic therapy 
3 Chemotherapy type (for those specified): anthracyclines (N=584), taxane + anthracycine (N=348), taxane + 
other; e.g. TCH, TCarbo (N=83), other (N=3) 
 
  
30 
 
Table 2: Relapse and mortality by fractionation schedule: results of time to event 
analyses for 4096 patients consenting to the FAST-Forward trial 
 Cumulative 
no. of events 
/ total (%) 
KM estimate 
(95%CI) of 
cumulative 
incidence by 5 
years, % 
Hazard ratio1  
(95% CI); p-value2 
 
Estimated 
absolute 
difference vs 
40 Gy at 5 
years3 
(95%CI), % 
Ipsilateral breast 
tumour (local) relapse4 
40 Gy 
27 Gy 
26 Gy 
 
 
31/1361 (2.3) 
27/1367 (2.0) 
21/1368 (1.5) 
 
 
2.1 (1.4, 3.1) 
1.7 (1.2, 2.6) 
1.4 (0.9, 2.2) 
 
 
1 
0.86 (0.51, 1.44); 0.56 
0.67 (0.38, 1.16); 0.15 
 
 
 
-0.3 (-1.0, 0.9) 
-0.7 (-1.3, 0.3) 
Locoregional relapse5 
40 Gy  
27 Gy 
26 Gy 
 
43/1361 (3.2) 
35/1367 (2.6) 
29/1368 (2.1) 
 
2.8 (2.0, 3.9) 
2.3 (1.6, 3.3) 
1.8 (1.2, 2.7) 
 
1 
0.80 (0.51, 1.25); 0.33 
0.66 (0.41, 1.06); 0.083 
 
 
-0.5 (-1.4, 0.7) 
-0.9 (-1.6, 0.2) 
Distant relapse 
40 Gy 
27 Gy 
26 Gy 
 
59/1361 (4.3) 
69/1367 (5.0) 
76/1368 (5.6) 
 
3.8 (2.9, 5.0) 
4.7 (3.7, 6.0) 
5.1 (4.0, 6.4) 
 
1 
1.16 (0.82, 1.64); 0.41 
1.27 (0.90, 1.79); 0.17 
 
 
0.6 (-0.7, 2.3) 
1.0 (-0.4, 2.9) 
Any breast cancer-
related event6 
40 Gy  
27 Gy 
26 Gy 
 
 
119/1361 (8.7) 
112/1367 (8.2) 
114/1368 (8.3) 
 
 
7.8 (6.5, 9.4) 
7.2 (5.9, 8.7) 
7.5 (6.2, 9.0) 
 
 
1 
0.93 (0.71, 1.20); 0.56 
0.94 (0.73, 1.22); 0.65 
 
 
 
-0.6 (-2.2, 1.5) 
-0.4 (-2.1, 1.6) 
All-cause mortality 
40 Gy 
27 Gy 
26 Gy 
 
92/1361 (6.8) 
105/1367 (7.7) 
90/1368 (6.6) 
 
5.4 (4.3, 6.8) 
6.9 (5.7, 8.4) 
5.6 (4.5, 7.0) 
 
1 
1.12 (0.85, 1.48); 0.42 
0.96 (0.72, 1.28); 0.78 
 
 
0.6 (-0.8, 2.5) 
-0.2 (-1.5, 1.5) 
KM = Kaplan-Meier, 95%CI = 95% confidence interval; IBTR = ipsilateral breast tumour relapse 
1 Hazard ratio <1 favours 5-fraction schedules;  
2 Log-rank test (2-sided), for each 5-fraction schedule compared with 40Gy/15fr (control);  
3 Estimated absolute difference at 5 years for each 5-fraction schedule versus 40Gy obtained from hazard 
ratio and KM estimate of cumulative incidence in 40Gy group; 
4 Includes 3 with angiosarcoma in ipsilateral breast (1 in 40Gy, 2 in 26Gy); 
5 Locoregional relapse defined as IBTR or regional relapse (axilla, supraclavicular fossa and internal 
mammary chain); 
6 Breast cancer-related events: local, regional or distant relapse, breast cancer death, contralateral breast 
cancer (disease-free survival) 
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Table 3: Relapses, second primary cancers and deaths by fractionation schedule, in 
4096 patients consenting to the FAST-Forward trial 
Event 
40 Gy / 15 Fr 27 Gy / 5 Fr 26 Gy / 5 Fr 
N=1361 (%) N=1367 (%) N=1368 (%) 
Local tumour control event  
(primary endpoint)1,2 
31 (2.3) 27 (2.0) 21 (1.5) 
Local relapse 23 22 17 
Ipsilateral breast new primary 6 3 4 
Cannot differentiate 2 2 0 
      
Regional relapse 13 (1.0) 11 (0.8) 10 (0.7) 
      
Distant relapse 59 (4.3) 69 (5.0) 76 (5.5) 
      
Contralateral breast second primary 
Invasive 
DCIS 
Unknown 
23 (1.7) 
18 
5 
0 
20 (1.5) 
17 
3 
0 
23 (1.7) 
20 
2 
1 
      
Non-breast second primary 42 (3.1) 37 (2.7) 44 (3.2) 
      
Death 92 (6.8) 105 (7.7) 90 (6.6) 
Breast cancer3 47 51 53 
Second cancer 12 16 10 
Cardiac 10 9 8 
Other cause 17 27 16 
Unknown 6 2 3 
NB: Patients reporting events of more than one type are included in each relevant row  
1 Includes angiosarcoma in ipsilateral breast (1 in 40Gy, 2 in 26Gy) 
2 Includes 6 patients with ductal carcinoma in situ, DCIS (3 in 40Gy, 2 in 27Gy, 1 in 26Gy) 
3 Includes 13 patients with distant relapse before death from other causes (4 in 40Gy, 4 in 27Gy, 5 in 26Gy) 
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Table 4: Longitudinal analysis of moderate/marked clinician-assessed late normal tissue effects including all annual 
follow-up assessments for 3975 patients with at least one annual clinical assessment 
Normal tissue effect 
No. 
moderate/marked 
events / total no. of 
assessments over 
follow-up (%) 
Odds ratio for  
schedule2 (95%CI) 
Comparison with  
40 Gy; 
p-value3 
Comparison between 
27 Gy & 26 Gy; 
p-value3 
Odds ratio for years 
of follow-up (95%CI);  
p-value3 
Any AE in the 
breast/chest wall1+ 
 
   0.98 (0.96,1.00); 
40 Gy 651/6121 (10.6) 1   0.055 
27 Gy 1004/6303 (15.9) 1.55 (1.32,1.83) <0.0001   
26 Gy 774/6327 (12.2) 1.12 (0.94,1.34) 0.20 0.0001  
Breast distortion*     0.99 (0.95,1.02); 
40 Gy 232/5724 (4.0) 1   0.38 
27 Gy 363/5953 (6.1) 1.51 (1.15,1.97) 0.0028   
26 Gy 299/5945 (5.0) 1.20 (0.91,1.60) 0.19 0.083  
Breast shrinkage*     1.03 (1.00,1.06); 
40 Gy 330/5728 (5.8) 1   0.023 
27 Gy 503/5944 (8.5) 1.50 (1.20,1.88) 0.0004   
26 Gy 369/5943 (6.2) 1.05 (0.82,1.33) 0.71 0.0018  
Breast induration (tumour 
bed)* 
    1.00 (0.96,1.04); 
40 Gy 185/5713 (3.2) 1   0.95 
27 Gy 304/5948 (5.1) 1.56 (1.19,2.05) 0.0013   
26 Gy 236/5937 (4.0) 1.19 (0.90,1.59) 0.23 0.047  
Breast induration 
(outside tumour bed)* 
    0.96 (0.90,1.02); 
40 Gy 45/5712 (0.8) 1   0.17 
27 Gy 137/5943 (2.3) 2.79 (1.74,4.50) <0.0001   
26 Gy 97/5930 (1.6) 1.90 (1.15,3.14) 0.013 0.059  
Telangiectasia+     1.21 (1.14,1.29); 
40 Gy 63/6087 (1.0) 1   <0.0001 
27 Gy 100/6272 (1.6) 1.68 (1.07,2.65) 0.025   
26 Gy 102/6300 (1.6) 1.53 (0.96,2.43) 0.070 0.65  
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Normal tissue effect 
No. 
moderate/marked 
events / total no. of 
assessments over 
follow-up (%) 
Odds ratio for  
schedule2 (95%CI) 
Comparison with  
40 Gy; 
p-value3 
Comparison between 
27 Gy & 26 Gy; 
p-value3 
Odds ratio for years 
of follow-up (95%CI);  
p-value3 
Breast / chest wall 
oedema+ 
    0.73 (0.69,0.78); 
40 Gy 89/6097 (1.5) 1   <0.0001 
27 Gy 217/6287 (3.4) 2.18 (1.57,3.03) <0.0001   
26 Gy 155/6318 (2.4) 1.47 (1.03,2.09) 0.032 0.0097  
Breast / chest wall 
discomfort+ 
    0.93 (0.89,0.97); 
40 Gy 234/6086 (3.8) 1   0.0003 
27 Gy 269/6285 (4.3) 1.10 (0.86,1.40) 0.44   
26 Gy 250/6309 (4.0) 0.98 (0.76,1.26) 0.86 0.35  
1 Any AE in breast includes shrinkage, induration, telangiectasia, oedema; 2 OR estimated from GEE model including all follow-up data, and represents 
relative odds of moderate/marked AE (versus none/mild) for each pairwise comparison of fractionation schedules across all follow-up assessments; 3 p-value 
from Wald test. * BCS and mastectomy patients; + BCS patients and mastectomy patients with reconstruction  
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Table 5: Longitudinal analysis of moderate/marked patient-assessed late normal tissue effects from baseline to 5 years for 
1774  patients with at least one completed questionnaire 
Normal tissue effect 
No. patients 
reporting 
moderate / marked 
event at baseline / 
total (%) 
No. 
moderate/marked 
events / total no. 
of assessments 
over 3-60 months 
follow-up (%) 
Odds ratio for 
schedule2 
(95%CI) 
Comparison with 
40 Gy; 
p-value3 
Comparison 
between 27 Gy & 
26 Gy; 
p-value3 
Odds ratio for 
years of 
follow-up 
(95%CI);  
p-value3 
Protocol-specific items 
Breast appearance 
changed 
     
1.03  
(1.01, 1.05); 
40 Gy 170/573 (29.7) 778/2480 (31.4) 1   0.0010 
27 Gy 177/583 (30.4) 929/2550 (36.4) 1.22 (1.02, 1.46) 0.033   
26 Gy 155/581 (26.7) 770/2563 (30.0) 0.91 (0.75, 1.10) 0.33 0.0018  
Breast smaller      
1.11 
(1.09, 1.13); 
40 Gy 96/560 (17.1) 585/2445 (23.9) 1   <0.0001 
27 Gy 106/576 (18.4) 606/2520 (24.0) 1.05 (0.85, 1.29) 0.67   
26 Gy 90/574 (15.7) 515/2542 (20.3) 0.81 (0.65, 1.00) 0.053 0.017  
Breast harder/firmer      
0.95 
(0.93, 0.97); 
40 Gy 94/558 (16.8) 499/2446 (20.4) 1   <0.0001 
27 Gy 105/572 (18.4) 690/2512 (27.5) 1.42 (1.17, 1.72) 0.0003   
26 Gy 95/566 (16.8) 626/2534 (24.7) 1.22 (1.00, 1.48) 0.048 0.1007  
Skin appearance 
changed 
     
0.96  
(0.93, 0.99); 
40 Gy 78/577 (13.5) 345/2505 (13.8) 1   0.0080 
27 Gy 61/586 (10.4) 392/2571 (15.2) 1.03 (0.83, 1.28) 0.77   
26 Gy 67/580 (11.5) 338/2576 (13.1) 0.90 (0.72, 1.13) 0.37 0.23  
EORTC QLQ-BR23 items 
Breast pain      
0.96 
(0.94, 0.99); 
40 Gy 53/583 (9.1) 338/2538 (13.3) 1   0.011 
27 Gy 42/590 (7.1) 428/2601 (16.5) 1.23 (0.98, 1.54) 0.068   
26 Gy 53/588 (9.0) 417/2597 (16.1) 1.23 (0.98, 1.53) 0.074 0.96  
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Normal tissue effect 
No. patients 
reporting 
moderate / marked 
event at baseline / 
total (%) 
No. 
moderate/marked 
events / total no. 
of assessments 
over 3-60 months 
follow-up (%) 
Odds ratio for 
schedule2 
(95%CI) 
Comparison with 
40 Gy; 
p-value3 
Comparison 
between 27 Gy & 
26 Gy; 
p-value3 
Odds ratio for 
years of 
follow-up 
(95%CI);  
p-value3 
Breast swollen      
0.84 
(0.80, 0.89); 
40 Gy 56/583 (9.6) 122/2538 (4.8) 1   <0.0001 
27 Gy 43/589 (7.3) 236/2597 (9.1) 1.46 (1.10, 1.94) 0.0080   
26 Gy 47/589 (8.0) 192/2599 (7.4) 1.27 (0.95, 1.69) 0.11 0.22  
Breast oversensitive      
0.96 
(0.93, 0.99); 
40 Gy 57/579 (9.8) 283/2528 (11.2) 1   0.0097 
27 Gy 42/584 (7.2) 334/2596 (12.9) 1.10 (0.87, 1.40) 0.43   
26 Gy 62/586 (10.6) 319/2587 (12.3) 1.11 (0.88, 1.41) 0.37 0.91  
Skin problems in 
breast 
     
0.96 
(0.92, 1.01); 
40 Gy 26/582 (4.5) 156/2539 (6.1) 1   0.11 
27 Gy 24/290 (4.1) 209/2596 (8.0) 1.25 (0.95, 1.65) 0.11   
26 Gy 18/590 (3.0) 164/2592 (6.3) 0.98 (0.73, 1.31) 0.90 0.084  
Arm / shoulder pain      
1.00 
(0.97, 1.03); 
40 Gy 66/582 (11.3) 401/2537 (15.8) 1   >0.99 
27 Gy 78/591 (13..2) 441/2601 (17.0) 1.12 (0.91, 1.37) 0.29   
26 Gy 81/589 (13.7) 455/2599 (17.5) 1.14 (0.93, 1.40) 0.2006 0.83  
Arm / hand swollen      
1.06 
(1.00, 1.11); 
40 Gy 24/582 (4.1) 101/2536 (4.0) 1   0.031 
27 Gy 17/588 (2.9) 103/2600 (4.0) 0.95 (0.66, 1.36) 0.77   
26 Gy 22/590 (3.7) 124/2592 (4.8) 1.14 (0.80, 1.62) 0.46 0.31  
Difficulty raising arm      
1.04 
(0.99, 1.08); 
40 Gy 27/582 (4.6) 171/2533 (6.7) 1   0.089 
27 Gy 36/589 (6.1) 209/2599 (8.0) 1.24 (0.94, 1.63) 0.12   
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Normal tissue effect 
No. patients 
reporting 
moderate / marked 
event at baseline / 
total (%) 
No. 
moderate/marked 
events / total no. 
of assessments 
over 3-60 months 
follow-up (%) 
Odds ratio for 
schedule2 
(95%CI) 
Comparison with 
40 Gy; 
p-value3 
Comparison 
between 27 Gy & 
26 Gy; 
p-value3 
Odds ratio for 
years of 
follow-up 
(95%CI);  
p-value3 
26 Gy 37/587 (6.3) 188/2596 (7.2) 1.12 (0.85, 1.48) 0.42 0.46  
2 OR estimated from GEE model including all questionnaires (baseline to 5 years), and represents relative odds of moderate/marked AE (versus none/mild) 
for each pairwise comparison of fractionation schedules across all questionnaires; 3 p-value from Wald test  
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